Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.
Crucitti A. Curr Med Res Opin. Nov 2010; 26(11): 2579-88 Pubmed[12934]
Cruddas L. J Eur Acad Dermatol Venereol. Jun 2017; 31(6): 952-963 Pubmed[6951]
Crussell-Porter LL. Arch Intern Med. Jan 1993; 153(1): 102-4 Pubmed[5892]
Cruz Rodriguez JB. Ann Transl Med. Mar 2021; 9(6): 519 Pubmed[11045]
Csajka C. Clin Pharmacokinet. Dec 2016; 55(12): 1521-1533 Pubmed[7562]
Csik V, Molnar J. Possible adverse interaction between clozapine and ampicillin in an adolescent with schizophrenia. J Child Adolesc Psychopharmacol (1994) 4, 123-8 [1108]
Csuka M. JAMA. May 1986; 255(17): 2315-9 Pubmed[8882]
Cuadrado A et al. Method Find exp Clin Pharmacol (1996) 18 (Suppl C), 65 [717]
Cuadrado A. Eur J Pharmacol. Mar 2003; 465(1-2): 43-52 Pubmed[9500]
Cuadrado A. Pharmacol Res. May 2005; 51(5): 489-96 Pubmed[9321]
Curtis BR. Immunohematology. Jan 2014; 30(2): 95-101 Pubmed[8144]
Curtis LH. Am J Med. Feb 2003; 114(2): 135-41 Pubmed[4943]
Cusato J. J Antimicrob Chemother. Jun 2018; 73(6): 1659-1664 Pubmed[7206]
Custodio J, West S, Vu A, et al., Lack of clinically relevant effect of bictegravir on metformin pharmacokinetics and pharmacodynamics. Paper presented at: 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; 2017; Chicago, IL. Available from: http://www.natap.org/2017/Pharm/Pharm_32.htm. Accessed May 29, 2018. [7479]
Custodio J, West S, Vu A, et al., Lack of clinically relevant effect of bictegravir on metformin pharmacokinetics and pharmacodynamics. Paper presented at: 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; 2017; Chicago, IL. Available from: http://www.natap.org/2017/Pharm/Pharm_32.htm. Accessed May 29. [7478]
Custodio J, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018. [7488]
Custodio J, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018. [7489]
Custodio J, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018. [7490]
Custodio J, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018.. [7486]
Custodio J, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018.. [7487]
Custodio JM. J Clin Pharmacol. Jun 2014; 54(6): 649-56 Pubmed[6670]
Custodio JM. Pharmacol Res Perspect. Oct 2017; 5(5) Pubmed, Volltext, DOI[7437]
Custodio, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018.. [7483]
Custodio, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018.. [7484]
Custodio, West S, Vu A, et al., Pharmacokinetics of bictegravir administered twice daily with rifampin. Paper presented at: The Conference on Retroviruses and Opportunistic Infections (CROI); 2018; Boston, MA. Available from: http://www.croiconference.org/sessions/ pharmacokinetics-bictegravir-administered-twice-daily-combinationrifampin. Accessed May 29, 2018.. [7485]
Czuczwar M. Pol J Pharmacol. Sep 2003; 55(5): 799-802 Pubmed[759]
Czuczwar SJ. Expert Opin Drug Metab Toxicol. Feb 2009; 5(2): 131-6 Pubmed[9278]
Czyrak A. Arzneimittelforschung. Feb 1994; 44(2): 113-8 Pubmed[11064]
D. Schmidt, G. Eckermann, U. Fuhr, G. Luef, B.J. Steinhoff, C.E.Elger, Arzneimittelinteraktionen bei der medikamentösen Epilepsietherapie: ein kritischer Überblick, Nervenheilkunde (Nov. 2007) [2766]
D. Schmidt, G. Eckermann, U. Fuhr, G. Luef, B.J. Steinhoff, C.E.Elger. Nervenheilkunde 2007; 26(11): 969-980. Nov 2007; 26(11): 969-980 Pubmed[12553]
D. Schmidt, G. Eckermann, U. Fuhr, G. Luef, B.J. Steinhoff, C.E.Elger. Nervenheilkunde 2007; 26(11): 969-980. Nov 2007; 26(11): 969-980. Nov 0207; 26(11): 969-980 Pubmed[12554]
D'Arrigo C. Pharmacol Res. Dec 2005; 52(6): 497-501 Pubmed[2687]
D'Cunha R. Biopharm Drug Dispos. Oct 2016; 37(7): 397-408 Pubmed[7615]